Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study-Reference-Cited by-同舟云学术

Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

Published:2021-03-01 Issue:3 Volume:187 Page:903-913
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

O’Shaughnessy Joyce,Robert Nicholas,Annavarapu Srinivas^ORCID,Zhou Jie,Sussell Jesse,Cheng Anna,Fung Anita

Funder

Genentech

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-021-06137-3.pdf

Reference22 articles.

1. National Cancer Institute, SEER Cancer Stat Facts: Female Breast Cancer (2020). https://seer.cancer.gov/statfacts/html/breast.html. Accessed 14 Sept 2020

2. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368. https://doi.org/10.1634/theoncologist.2008-0230

3. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43. https://doi.org/10.1043/1543-2165(2007)131[18:asocco]2.0.co;2

4. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475. https://doi.org/10.1038/nrc2656

5. Agus DB, Akita RW, Fox WD et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137. https://doi.org/10.1016/s1535-6108(02)00097-1

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic Characterization of a 3D HER2+ Breast Cancer Model Reveals the Role of Mitochondrial Complex I in Acquired Resistance to Trastuzumab;International Journal of Molecular Sciences;2024-07-05

2. Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience;Cancer Medicine;2024-06

3. The neoadjuvant systemic treatment of early breast cancer: a narrative review;Annals of Breast Surgery;2023-12

4. Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer;The Breast;2023-12

5. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study;Frontiers in Oncology;2023-10-02